Raia Drogasil S.A. (RADLY)
USD 3.37
(-4.8%)
USD 3.37
(-4.8%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.75 Billion BRL | -15.64% |
| 2022 | 2.45 Billion BRL | 17.49% |
| 2021 | 2.63 Billion BRL | 25.5% |
| 2020 | 2.03 Billion BRL | 11.25% |
| 2019 | 1.82 Billion BRL | 66.03% |
| 2018 | 1.09 Billion BRL | 7.0% |
| 2017 | 1.11 Billion BRL | 16.14% |
| 2016 | 965.93 Million BRL | 32.83% |
| 2015 | 716.71 Million BRL | 35.78% |
| 2014 | 539.8 Million BRL | 63.41% |
| 2013 | 371.32 Million BRL | 5.66% |
| 2012 | 284.21 Million BRL | 80.25% |
| 2011 | 157.67 Million BRL | 0.03% |
| 2010 | 157.63 Million BRL | 19.56% |
| 2009 | 131.84 Million BRL | 166.61% |
| 2008 | 49.45 Million BRL | -1.8% |
| 2007 | 50.36 Million BRL | -12.91% |
| 2006 | 43.09 Million BRL | 147.07% |
| 2005 | 23.4 Million BRL | -0.79% |
| 2004 | 23.59 Million BRL | 3.07% |
| 2003 | 22.89 Million BRL | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 961.57 Million BRL | 94.62% |
| 2024 Q2 | 1.1 Billion BRL | 12.93% |
| 2023 Q4 | 375.03 Million BRL | -56.98% |
| 2023 Q3 | 871.76 Million BRL | -11.76% |
| 2023 Q1 | 684.44 Million BRL | 14.92% |
| 2023 Q2 | 987.97 Million BRL | 44.35% |
| 2023 FY | - BRL | -15.64% |
| 2022 Q4 | 595.57 Million BRL | -27.27% |
| 2022 Q1 | 546.84 Million BRL | -25.13% |
| 2022 Q2 | 932.81 Million BRL | 70.58% |
| 2022 FY | - BRL | 17.49% |
| 2022 Q3 | 818.89 Million BRL | -12.21% |
| 2021 Q3 | 580.27 Million BRL | -20.73% |
| 2021 FY | - BRL | 25.5% |
| 2021 Q4 | 730.37 Million BRL | 25.87% |
| 2021 Q1 | 597.68 Million BRL | -2.11% |
| 2021 Q2 | 732.01 Million BRL | 22.47% |
| 2020 Q1 | 519.43 Million BRL | 69.48% |
| 2020 Q2 | 385.66 Million BRL | -25.75% |
| 2020 Q4 | 610.58 Million BRL | 8.77% |
| 2020 FY | - BRL | 11.25% |
| 2020 Q3 | 561.37 Million BRL | 45.56% |
| 2019 Q3 | 451.51 Million BRL | -5.8% |
| 2019 FY | - BRL | 66.03% |
| 2019 Q1 | 355.05 Million BRL | 182.64% |
| 2019 Q2 | 479.3 Million BRL | 34.99% |
| 2019 Q4 | 306.48 Million BRL | -32.12% |
| 2018 Q1 | 257.67 Million BRL | 149.53% |
| 2018 FY | - BRL | 7.0% |
| 2018 Q4 | 125.62 Million BRL | -52.9% |
| 2018 Q3 | 266.71 Million BRL | -6.83% |
| 2018 Q2 | 286.27 Million BRL | 11.1% |
| 2017 Q1 | 215.07 Million BRL | 289.72% |
| 2017 Q4 | 103.26 Million BRL | -61.79% |
| 2017 FY | - BRL | 16.14% |
| 2017 Q3 | 270.23 Million BRL | -1.61% |
| 2017 Q2 | 274.65 Million BRL | 27.7% |
| 2016 Q4 | 55.18 Million BRL | -75.52% |
| 2016 FY | - BRL | 32.83% |
| 2016 Q1 | 177.44 Million BRL | 221.3% |
| 2016 Q3 | 225.45 Million BRL | -20.11% |
| 2016 Q2 | 282.21 Million BRL | 59.04% |
| 2015 FY | - BRL | 35.78% |
| 2015 Q2 | 202.89 Million BRL | 46.75% |
| 2015 Q4 | 55.22 Million BRL | -66.83% |
| 2015 Q3 | 166.51 Million BRL | -17.93% |
| 2015 Q1 | 138.26 Million BRL | 11.23% |
| 2014 FY | - BRL | 63.41% |
| 2014 Q1 | 84.49 Million BRL | 24.56% |
| 2014 Q2 | 127.37 Million BRL | 50.74% |
| 2014 Q3 | 136.12 Million BRL | 6.87% |
| 2014 Q4 | 124.3 Million BRL | -8.68% |
| 2013 Q4 | 67.83 Million BRL | -0.75% |
| 2013 FY | - BRL | 5.66% |
| 2013 Q3 | 68.35 Million BRL | -26.2% |
| 2013 Q2 | 92.62 Million BRL | 59.96% |
| 2013 Q1 | 57.9 Million BRL | 3.59% |
| 2012 Q1 | 59.81 Million BRL | 90.0% |
| 2012 FY | - BRL | 80.25% |
| 2012 Q4 | 55.89 Million BRL | -28.02% |
| 2012 Q3 | 77.65 Million BRL | -20.37% |
| 2012 Q2 | 97.52 Million BRL | 63.04% |
| 2011 FY | - BRL | 0.03% |
| 2011 Q3 | 47.48 Million BRL | -7.46% |
| 2011 Q2 | 51.31 Million BRL | 130.83% |
| 2011 Q1 | 22.22 Million BRL | -54.12% |
| 2011 Q4 | 31.48 Million BRL | -33.69% |
| 2010 Q1 | 29.04 Million BRL | -33.4% |
| 2010 FY | - BRL | 19.56% |
| 2010 Q4 | 48.45 Million BRL | 35.62% |
| 2010 Q3 | 35.72 Million BRL | -27.09% |
| 2010 Q2 | 49 Million BRL | 68.7% |
| 2009 FY | - BRL | 166.61% |
| 2009 Q4 | 43.61 Million BRL | 31.95% |
| 2009 Q3 | 33.05 Million BRL | -12.53% |
| 2009 Q2 | 37.78 Million BRL | 54.43% |
| 2009 Q1 | 24.46 Million BRL | 0.0% |
| 2008 FY | - BRL | -1.8% |
| 2007 FY | - BRL | -12.91% |
| 2006 FY | - BRL | 147.07% |
| 2005 FY | - BRL | -0.79% |
| 2004 FY | - BRL | 3.07% |
| 2003 FY | - BRL | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alternative Energy Partners, Inc. | -251.11 USD | 1096001852.22% |
| Allstar Health Brands, Inc. | -241.78 Thousand USD | 1138362.189% |
| Beijing Tong Ren Tang Chinese Medicine Company Limited | 89.4 Million USD | -2978.454% |
| Café Serendipity Holdings, Inc. | -1.41 Million USD | 194558.968% |
| Decision Diagnostics Corp. | - USD | -Infinity% |
| Health Advance Inc. | -47.95 Thousand USD | 5738808.87% |
| HealthWarehouse.com, Inc. | -1.27 Million USD | 215904.508% |
| LIGAND PHARMACEUTICAL INC | 47.23 Million USD | -5726.918% |
| MedGen, Inc. | -15.37 USD | 17906115910.02% |
| Omni Health, Inc. | 1.28 Million USD | -213644.507% |
| Oxford Investments Holdings Inc. | -343.96 Thousand USD | 800228.501% |
| Pineapple, Inc. | -1.47 Million USD | 186652.636% |
| ScripsAmerica, Inc. | -3.95 Million USD | 69696.467% |